According to CEO Albert Boerla, Pfizer may have data on how well its COVID-19 vaccine works in children under the age of 5 by the end of the year.
“We studied another group of children aged 6 months to 2 years, and then children aged 2 to 5 years,” Bourla told Granthshala News chief White House correspondent Kristen Welker. “Therefore [by] At the end of the year, early next year, we will know more when we see the figures.”
As the Omicron variant begins to spread globally, there are concerns about the risk to young children. At a briefing on Friday in South Africa, where the virus was first identified and infections were on the rise, a top scientist said medical staff had begun to see an increase in admissions for children under the age of 4. .
Full coverage of the COVID-19 pandemic
Moderna’s CEO Stephen Bunsell, who is the US Senate’s Edward M. Barla, who joined the Kennedy Institute in a joint interview, also said that his company is testing its vaccine in children, though he did not say when the data might have been available.
Last month, Moderna announced that US regulators were delaying their decision on the company’s vaccine for children 12 to 17 years old while they study a rare risk of heart inflammation, known as myocarditis. which has been observed in a small number of young men. shot received.
“With children, you want to go down in age very slowly … and start with a low dose and then gradually increase the dosage level to find the right dose.” “So it’s going to take a little longer because the safety of those kids in those studies is very important to all of us.”
The comments from pharmaceutical executives come as the Biden administration is urging all eligible Americans to receive a booster shot of the COVID-19 vaccine over concerns about the continued spread of Omicron variants and highly transmissible delta variants.
The Omicron variant, in particular, has mutations that suggest it may evade the protection provided by vaccination or natural infection.
download nbc news app For full coverage of the COVID-19 pandemic
Pfizer’s vaccine is approved for people younger than 5 years old, while Moderna’s vaccine is authorized for adults. The only group in the US not eligible to get the shot are children under the age of 5.
In an interview with Granthshala News, Bansel urged the public to “remain calm” as federal health officials and drugmakers await data on how well existing COVID-19 shots work against the new version.
“We’re looking at all the data because it’s part of the dataset that’s slowly building up, but in a few weeks it will be smarter about how the virus behaves,” he said.
Credit: www.nbcnews.com /